Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
October 15, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
September 26, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Data on Delcath’s PHP Therapy presented at CIRSE 2018
September 24, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
August 23, 2018 11:14 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
August 21, 2018 08:52 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
August 20, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Amends Phase 3 Ocular Melanoma Trial Protocol
July 27, 2018 08:00 ET
|
Delcath Systems, Inc.
Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019 NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) --...
Delcath Systems to Present at the 8th Annual LD Micro Invitational
May 29, 2018 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced...
Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
May 22, 2018 08:15 ET
|
Delcath Systems, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to...
Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
May 16, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...